Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a biotechnology company that develops and distributes prescription medical foods to physicians and pharmacies, today announced the launch of a new division that will specialize in the manufacturing and distribution of a proprietary line of dietary supplements.
“We are pleased to announce the development of an over-the-counter product line and introduce a new technology that enhances the digestion processes by allowing salivary enzymes to function”
The products, currently in the research and development phase, include a nasal decongestant, sleep aid, an appetite suppressant, a formula for pain and a formula that supports healthy cognitive performance. The products utilize the company's patented targeted cellular technology platform to increase the effectiveness of milligram amounts of neurotransmitter precursors and "swish and swallow" system that is designed to allow digestive enzymes in saliva to initiate and facilitate digestion.
The first product is scheduled to be launched on November 1, 2013, and will be an oral dietary supplement featuring a proprietary sinuhealth blend designed to support healthy sinus and immune function, and help relieve nasal congestion, sinus pressure and runny nose associated with allergies and colds.
"We are pleased to announce the development of an over-the-counter product line and introduce a new technology that enhances the digestion processes by allowing salivary enzymes to function," said William Shell, M.D., CEO and Chief Scientific Officer of Targeted Medical Pharma, Inc. "Our company is committed to innovating healthcare processes and providing physicians, patients, and health conscious consumers with the most effective and safe therapeutic options for health and wellness."
SOURCE Targeted Medical Pharma, Inc.